<DOC>
	<DOCNO>NCT02936492</DOCNO>
	<brief_summary>Systemic safety follow single multiple dermal administration BAY1003803</brief_summary>
	<brief_title>BAY1003803 Single Multiple Dose Escalation , Safety , Tolerability Pharmacokinetics Study</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Healthy male subject Age : 18 64 year ( inclusive ) first screen visit Body mass index ( BMI ) : equal 18 equal 30 kg / mÂ² first screen visit Nonsmoker least 3 month prior study start study Healthy skin redden easily recognize A history relevant diseases , especially incompletely cured preexisting disease assume absorption , distribution , excretion effect study drug normal , dermal disease , diseases present risk subject treat glucocorticoid receptor agonist ( e.g . gastric ulcer , cornea ulcer , colitis ulcerosa , severe infection , glaucoma , diabetes , myocardial infarction , thromboembolic disease , hypertension , thyroid disease , tuberculosis , myasthenia gravis , osteoporosis , psychiatric disease ) Infections febrile illness within 4 week first study drug administration Use systemic topical medicine substance oppose study objective might influence Inoculations live vaccine within 8 week first study drug administration Signs irritation folliculitis dermatological condition test area would interfere planned assessment judge Investigators Human leukocyte antigenDR ( HLADR ) &lt; 15000 AB/monocyte</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>